Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was up +2.7% at $3.80. The stock's performance was ahead of the S&P 500's daily gain of 0.7%. Elsewhere, the Dow saw an upswing of 0.28%, ...

Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its ...

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, ...

Recursion (RXRX) stock dips after $200M equity offering despite Sanofi (SNY) choosing its first AI drug candidate under a research deal between the two. Read more here.

Key TakeawaysAbsci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves. Schrödinger’s rally has the most business behind it, and Absci’s rally is ...

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term catalysts. Click for more on RXRX.

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of ...